BRAF and neoplasm: Therefore, molecular profiling has become essential and the guidelines recommend that all patients with mCRC should type tumor tissue for RAS (KRAS and NRAS) and BRAF mutations [13,14], and microsatellite instability (MSI) or mismatch repair (MMR) testing, as there are specific treatment options for wild-type RAS, BRAF V600E mutant and MSI mCRC [15].